ABSTRACT
We investigated 212 patients attending 3 diabetic clinics centres in Lagos; Nigeria; and recorded family history; age of onset of diabetes; and body mass index. Analysis of family pedigrees showed that 3of sibships followed an autosomal dominant pattern of inheritance. The mean age of diabetes onset among the dominant group was 25 years and obesity was uncommon. This suggests that these patients may have Maturity Onset Diabetes of the Young (MODY)
Subject(s)
Diabetes Mellitus , ObesityABSTRACT
The prevalence of multidrug-resistant shigellae is an important concern in the treatment of shigellosis in many developing countries, and other therapies, including herbal agents, may provide an important alternative to antimicrobial agents. In this study, three Nigerian medicinal plants: Ocimum gratissimum, Terminalia avicennoides, and Momordica balsamina were investigated for their activities against multidrug-resistant Shigella species isolated from patients with bacilliary dysentery in Lagos. Decoctions of O. gratissimum and concoctions of O. gratissimum and T. avicennoides at crude concentration of 3,000 micrograms/mL markedly inhibited the growth of all isolates tested. Zones of inhibition indicating susceptibilities of the organisms varied from 18.3 to 21.5 mm for Shigella dysenteriae, 15.3 to 16.3 mm for S. flexneri, 18.8 to 19.3 mm for S. sonnei, and 16.5 mm for S. boydii. Except S. flexneri, minimum inhibitory concentration and minimum bactericidal concentration revealed a higher shigellocidal property of O. gratissimum/T. avicennoides concoction than other extracts in S. dysenteriae (300-515.6 vs 337.5-1,312.5 micrograms/mL), S. sonnei (309.4-543.8 vs 403.1-1,312.5 micrograms/mL), and S. boydii (243.8-337.5 vs 253-1,312.5 micrograms/mL). O. gratissimum showed a greater shigellocidal effect against the S. flexneri isolates, while extracts of M. balsamina possessed low shigellocidal potential. The results suggest that aqueous extracts of O. gratissimum and T. avicennoides as decoctions and concoctions could be useful in the treatment of shigellosis and should be clinically evaluated specially in Nigerian region.